Gilead Sciences (NASDAQ:GILD) Stock: Insider Andrew Dickinson Sells 3,000 Shares

Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report) CFO Andrew Dickinson sold 3,000 shares of the company’s stock in a transaction dated Monday, November 16th. The stock was sold at an average price of $171.47, for a total value of $514,410.00. Following the sale, the chief financial officer owned 158,096 shares in the company, valued at approximately $27,108,721.12. This trade represents a 1.86% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences Trading Down 0.8%

GILD stock opened at $168.98 on Thursday. The business’s 50-day moving average is $156.37 and its two-hundred day moving average is $142.23. The company has a quick ratio of 1.22, a current ratio of 1.38 and a debt-to-equity ratio of 1.84. Gilead Sciences, Inc. has a 1 year low of $116.88 and a 1 year high of $176.58.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last announced its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping analysts’ consensus estimates of $2.19 by $0.36. Gilead Sciences had a negative return on equity of 1.85% and a negative net margin of 12.47%. The business had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. During the same period in the previous year, the company posted $2.47 earnings per share. The business’s revenue for the quarter was up 6.8% on a year-over-year basis. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post -0.97 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be paid a $0.82 dividend. The ex-dividend date is Tuesday, December 15th. This represents a $3.28 dividend on an annualized basis and a yield of 1.9%. Gilead Sciences’s payout ratio is currently -103.80%.

Key Gilead Sciences News

These are some of the GILD news items that stood out recently:

  • Neutral Sentiment: Gilead completed a new research center in Foster City, adding specialized laboratory capacity that may support research over time, but carries no stated immediate financial impact. Article: Research center completion
  • Negative Sentiment: Barclays reaffirmed its Hold rating and cited a $160 price target, indicating limited upside at the share levels referenced in recent coverage. That cautious stance may weigh on sentiment. Article: Barclays reaffirms Hold rating
  • Negative Sentiment: CFO Andrew Dickinson sold 3,000 shares, and insider Johanna Mercier sold 28,000 shares. Both transactions were made under pre-arranged Rule 10b5-1 plans, which makes them less informative as signals about near-term company prospects, but insider sales can still add modest pressure to sentiment. Article: CFO share sale

Hedge Funds Weigh In On Gilead Sciences

Hedge funds have recently added to or reduced their stakes in the stock. BlackRock Inc. purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at $15,393,785,000. State Street Corp raised its stake in Gilead Sciences by 2.3% during the 2nd quarter. State Street Corp now owns 61,216,552 shares of the biopharmaceutical company’s stock worth $7,734,099,000 after acquiring an additional 1,357,967 shares in the last quarter. Amundi lifted its position in Gilead Sciences by 10.7% in the first quarter. Amundi now owns 10,539,111 shares of the biopharmaceutical company’s stock valued at $1,468,836,000 after acquiring an additional 1,018,976 shares during the last quarter. Legal & General Group Plc purchased a new stake in Gilead Sciences in the second quarter valued at $1,316,606,000. Finally, Deutsche Bank AG acquired a new position in Gilead Sciences in the second quarter valued at $918,387,000. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the stock. Royal Bank Of Canada increased their price objective on shares of Gilead Sciences from $126.00 to $131.00 and gave the company a “sector perform” rating in a research report on Friday, October 30th. Citigroup lifted their price objective on shares of Gilead Sciences from $165.00 to $188.00 and gave the stock a “buy” rating in a research report on Friday, October 30th. Truist Financial boosted their target price on shares of Gilead Sciences from $158.00 to $181.00 and gave the stock a “buy” rating in a research note on Friday, October 30th. Barclays boosted their target price on shares of Gilead Sciences from $145.00 to $160.00 and gave the stock an “equal weight” rating in a research note on Monday. Finally, Weiss Ratings raised Gilead Sciences from a “hold (c-)” rating to a “hold (c)” rating in a report on Monday, September 14th. Twenty-three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to data from MarketBeat.com, Gilead Sciences currently has a consensus rating of “Moderate Buy” and a consensus price target of $171.63.

Check Out Our Latest Stock Analysis on Gilead Sciences

About Gilead Sciences

(Get Free Report)

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.

Featured Articles

Insider Buying and Selling by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.